The European Commission approved Incyte’s PD-1 inhibitor Zynyz (retifanlimab) plus carboplatin and paclitaxel for metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal, after POD1UM-303/InterAACT2 showed a 37% lower risk of progression or death vs chemo alone and median PFS of 9.3 vs 7.4 months. But the FDA issued a complete response letter for Zynyz plus platinum-based chemotherapy in metastatic non–small-cell lung cancer, citing inspection findings at a third-party fill-finish site (Catalent, Indiana) used for the drug.

Why It Matters To Oncology

• Zynyz’s EU decision reinforces the PD-1 + chemotherapy backbone in GI/HPV-associated squamous malignancies, with a clinically meaningful PFS gain (9.3 vs 7.4 months) in a rare-disease setting.

• The NSCLC setback is manufacturing- and site-related rather than efficacy-related, but it still delays access to a high-volume indication where PD-(L)1 + platinum chemotherapy is standard.

• For drug discovery and development teams, it’s another reminder that CMC and supply-chain execution can be the rate-limiting step even late in Phase III/filing.

The Financials

• Incyte did not disclose new EU pricing or revenue expectations tied to the SCAC label expansion.

• The CRL introduces timing uncertainty for a potential NSCLC launch and can shift near-term commercial forecasts despite unchanged clinical data.

What They're Saying

• FDA’s CRL cited inspection findings at Novo Nordisk’s “troubled” Catalent site in Indiana that serves as Zynyz’s third-party fill-finish facility.

• Incyte said it is working with the FDA and Novo Nordisk to address the issues and noted the findings are not specific to Zynyz.

What's Next

• EU rollout: Incyte will move from approval to country-by-country access decisions for Zynyz + carboplatin/paclitaxel in SCAC.

• US path: remediation and reinspection/clearance of the fill-finish site will likely determine the timeline for resubmission and any NSCLC approval decision.

• Clinicians should watch for updated regulatory guidance on whether additional data are needed (vs a purely CMC-driven resubmission) and for any interim supply plans.